NextCure, Inc. (NASDAQ:NXTC) Short Interest Update

NextCure, Inc. (NASDAQ:NXTC) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 839,700 shares, a growth of 579.9% from the February 29th total of 123,500 shares. Based on an average trading volume of 229,500 shares, the short-interest ratio is currently 3.7 days. Currently, 4.0% of the company’s stock are short sold.

Wall Street Analyst Weigh In

NXTC has been the topic of a number of recent analyst reports. HC Wainwright boosted their price target on NextCure from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Needham & Company LLC reissued a “buy” rating and set a $4.00 price target on shares of NextCure in a research report on Wednesday, March 20th.

NextCure Stock Performance

Shares of NXTC traded up $0.30 during trading hours on Thursday, reaching $2.23. The stock had a trading volume of 1,014,865 shares, compared to its average volume of 254,665. NextCure has a 12 month low of $0.98 and a 12 month high of $2.28. The stock has a market capitalization of $62.22 million, a PE ratio of -0.93 and a beta of 0.37. The company’s 50-day moving average is $1.48 and its two-hundred day moving average is $1.31.

Institutional Trading of NextCure

A number of large investors have recently bought and sold shares of the business. Silverarc Capital Management LLC lifted its position in NextCure by 1.6% in the 1st quarter. Silverarc Capital Management LLC now owns 196,187 shares of the company’s stock valued at $953,000 after acquiring an additional 3,175 shares in the last quarter. State Street Corp lifted its position in NextCure by 10.7% in the 1st quarter. State Street Corp now owns 57,092 shares of the company’s stock valued at $277,000 after acquiring an additional 5,515 shares in the last quarter. UBS Group AG lifted its position in NextCure by 224.6% in the 1st quarter. UBS Group AG now owns 9,160 shares of the company’s stock valued at $45,000 after acquiring an additional 6,338 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in NextCure by 100.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 16,375 shares of the company’s stock valued at $45,000 after acquiring an additional 8,206 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in NextCure by 104.0% in the 1st quarter. JPMorgan Chase & Co. now owns 17,895 shares of the company’s stock valued at $87,000 after acquiring an additional 9,121 shares in the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.